ArticlePloS one2025
Community use of systemic antibiotics among individuals aged 15 and over in Brazil: A seven-year population-based cross-sectional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Brazil is recognized as the largest consumer of antibiotics among Latin American countries, despite the implementation of restrictive measures since 2011. Systemic antibiotics (J01) are commonly prescribed for community use and empirically for treating viral diseases, which can result in therapeutic failure and potential sources of microbial resistance. Studying the use of J01 at the outpatient and community level provides an opportunity to understand different clinical and social perspectives on the use of these drugs. The study aimed to describe the consumption of J01 in young people and adults in Brazil, based on dispensing from private community pharmacies. We conducted a cross-sectional study using data from January 2014 to December 2020, extracted from dispensing records in the National System for the Management of Controlled Products at the national, regional, and state levels. The primary consumption indicator used was the Defined Daily Dose per 1,000 inhabitants per day (DID). A total of 259,313,837 antibiotic dispensing records were collected during the period. Of this total, 67.2% were J01 and complied with other inclusion criteria established for the analysis. Over the period, 4,590,329,296 standard units were consumed in Brazil, characterized by a non-linear trend (p-value 0.357). Consumption ranged from 9.8 to 12.9 in DID. Penicillins (J01C) and macrolides (J01F) were the most consumed therapeutic groups, accounting for 28.1% and 28.6% of total J01 consumption, respectively, in terms of median usage. The analysis revealed that although overall consumption is increasing across the country, the patterns differ based on the distribution of dispensing records and DID values in various states. The results provide insights that can serve as a foundation for local health managers to analyze and interpret the data, promoting the development of surveillance and monitoring strategies for the use of J01.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.